Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy

Jung, Hee Won; Kim, Jin Won; Kim, Ji Yeon; Kim, Sun Wook; Yang, Hyun Kyoung; Lee, Joon Woo; Lee, Moon Hyoung; Kim, Duck Woo; Kang, Sung Bum; Kim, Kwang Il; Kim, Cheol Ho; Kim, Jee Hyun

doi:10.1007/s00520-014-2418-6

Cited by 194 publications

(200 citation statements)

References 39 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…Although in some studies a correlation between PA and post‐operative complications was seen, the majority have failed to prove a relationship between PA‐assessed sarcopenia and survival 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23. Only few have actually assessed the agreement between PA and SMA within their population; Jones et al studied 100 patients with colorectal cancer and reported a Spearman correlation of 0.8 for PA and SMA and a Spearman correlation of 0.94 for PA and PLW, which could not be reproduced in our cohort 11.…”

Section: Discussionmentioning

confidence: 99%

“…PA has shown a correlation with post‐operative complications in individual studies on colorectal cancer, colorectal liver metastases, kidney cancer, bladder cancer, cholangiocarcinoma, and hepatocellular cancer,11, 12, 13, 14, 15, 16 while this effect was not seen in other pancreatic cancer, endometrial cancer, biliary cancer, or sarcoma studies 17, 18, 19, 20. Interestingly, only few cancer studies were able to show a correlation between PA and survival 21, 22, 23. In a small number of non‐cancer studies, decreased psoas muscle area has also been correlated with higher rates of morbidity24, 25, 26 and mortality25, 27, 28, 29 in patients undergoing cardiothoracic, gastro‐intestinal, and spinal surgery.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Rutten

Ubachs

Kruitwagen

et al. 2017

J cachexia sarcopenia muscle

163

133

View full text Add to dashboard Cite

BackgroundComputed tomography measurements of total skeletal muscle area can detect changes and predict overall survival (OS) in patients with advanced ovarian cancer. This study investigates whether assessment of psoas muscle area reflects total muscle area and can be used to assess sarcopenia in ovarian cancer patients.MethodsOvarian cancer patients (n = 150) treated with induction chemotherapy and interval debulking were enrolled retrospectively in this longitudinal study. Muscle was measured cross sectionally with computed tomography in three ways: (i) software quantification of total skeletal muscle area (SMA); (ii) software quantification of psoas muscle area (PA); and (iii) manual measurement of length and width of the psoas muscle to derive the psoas surface area (PLW). Pearson correlation between the different methods was studied. Patients were divided into two groups based on the extent of change in muscle area, and agreement was measured with kappa coefficients. Cox‐regression was used to test predictors for OS.ResultsCorrelation between SMA and both psoas muscle area measurements was poor (r = 0.52 and 0.39 for PA and PLW, respectively). After categorizing patients into muscle loss or gain, kappa agreement was also poor for all comparisons (all κ < 0.40). In regression analysis, SMA loss was predictive of poor OS (hazard ratio 1.698 (95%CI 1.038–2.778), P = 0.035). No relationship with OS was seen for PA or PLW loss.ConclusionsChange in psoas muscle area is not representative of total muscle area change and should not be used to substitute total skeletal muscle to predict survival in patients with ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Rutten

Ubachs

Kruitwagen

et al. 2017

J cachexia sarcopenia muscle

163

133

View full text Add to dashboard Cite

show abstract

“…However, adjuvant chemotherapy was avoided for patients with sarcopenic condition at each physician's judgment. Sarcopenia is reportedly associated with increased risk of toxicity in patients with colon cancer who undergo adjuvant chemotherapy (17). If patients who will get benefit from adjuvant chemotherapy can be selected, a prognosis of patients with sarcopenia may improve.…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer

Tsukioka

Nishiyama

Izumi

et al. 2017

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives: Sarcopenia is the progressive loss of muscle mass and strength, and has a risk of adverse outcomes such as disability, poor quality of life and death. As prognosis depends not only on disease aggressiveness, but also on a patient's physical condition, sarcopenia can predict survival in patients with various cancer types. However, its effects on postoperative prognosis in patients with localized non-small cell lung cancers (NSCLC) have never been reported. Methods: We retrospectively investigated 215 male patients with pathological Stage I NSCLC. L3 muscle index is defined as the cross-section area of muscle at the third lumbar vertebra level, normalized for height, and is a clinical measurement of sarcopenia. We then investigated the effect of preoperative sarcopenia on their postoperative prognosis. Results: Our 215 subjects included 30 patients with sarcopenia. Sarcopenia was significantly associated with body mass index, nutritional condition, serum CYFRA 21-1 level and pathological stage, but not with preoperative respiratory function or performance status. Frequency of postoperative complications, length of postoperative hospital stay, thoracic drainage period or causes of death were not correlated with the presence of sarcopenia. The sarcopenia group had a significantly shorter median overall survival (32 months) than the no-sarcopenia group. Conclusion: Sarcopenia might not affect short-term outcomes in patients with early-stage lung cancer. Sarcopenia was a predictor of poor prognosis in male patients with Stage I NSCLC. As sarcopenic patients with NSCLC patients are at risk for significantly worse outcomes, their treatments require careful planning, even for those with Stage I disease.

show abstract

“…Furthermore, muscle wasting and low muscle mass have been linked to poorer survival and increased risk of treatment toxicity in various cancer diagnoses, including NSCLC 15, 16, 17, 18, 19. In advanced NSCLC, a recent study from our group showed that low muscle mass was a significant predictor for chemotherapy‐induced haematological toxicity 20…”

Section: Introductionmentioning

confidence: 99%

Muscle mass and association to quality of life in non‐small cell lung cancer patients

Bye

Sjøblom

Wentzel‐Larsen

et al. 2017

J cachexia sarcopenia muscle

121

137

View full text Add to dashboard Cite

BackgroundCancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected QoL outcomes in advanced non‐small cell lung cancer (NSCLC) at diagnosis.MethodsBaseline data from patients with stage IIIB/IV NSCLC and performance status 0–2 enrolled in three randomized trials of first‐line chemotherapy (n = 1305) were analysed. Associations between SMI (cm2/m2) and SMD (Hounsfield units) based on computed tomography‐images at the third lumbar level and self‐reported physical function (PF), role function (RF), global QoL, fatigue, and dyspnoea were investigated by linear regression using flexible non‐linear modelling.ResultsComplete data were available for 734 patients, mean age 65 years. Mean SMI was 47.7 cm2/m2 in men (n = 420) and 39.6 cm2/m2 in women (n = 314). Low SMI values were non‐linearly associated with low PF and RF (men P = 0.016/0.020, women P = 0.004/0.012) and with low global QoL (P = 0.001) in men. Low SMI was significantly associated with high fatigue (P = 0.002) and more pain (P = 0.015), in both genders, but not with dyspnoea. All regression analyses showed poorer physical outcomes below an SMI breakpoint of about 42–45 cm2/m2 for men and 37–40 cm2/m2 for women. In both genders, poor PF and more dyspnoea were significantly associated with low SMD.ConclusionsLow muscle mass in NSCLC negatively affects the patients' PF, RF, and global QoL, possibly more so in men than in women. However, muscle mass must be below a threshold value before this effect can be detected.

show abstract

Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy

Abstract: Decreased muscle mass was associated with increased risk of grade 3-4 toxicity and poor prognosis in patients with stage III colon cancer.

Cited by 194 publications

References 39 publications

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer

Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer

Muscle mass and association to quality of life in non‐small cell lung cancer patients

Contact Info

Product

Resources

About